All Episodes

Pier Luigi Zinzani, MD, PhD - Recognising and Responding to a Rare Disease: A Case-Based Exploration of the Ideal iMCD Patient Journey

Matthew J. Koster, MD - VEXAS Syndrome Asked and Answered: Everything You Want To Know And More

Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy

Rachel Soyoun Kim, MD, MHSc, FRCSC - From Evidence to Practice: Combining Immunotherapy With Chemoradiotherapy Regimens in Locally Advanced Cervical Cancer

Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies

Natasha Leighl, MD, MMSc, FRCPC, FASCO - Targeting Improved Outcomes in ALK-Positive NSCLC: A Canadian Clinician’s Guide to Optimizing Outcomes Across the Spectrum of Disease

Peter Schmid, FRCP, MD, PhD - Use of Neoadjuvant Chemoimmunotherapy Followed by Adjuvant Immunotherapy in Early-Stage TNBC: A Case-Based Discussion

Diana N. Ionescu, MD - Standardizing pCR Assessment in Early-Stage Breast Cancer: Evaluating Rationale, Methods, and Common Pitfalls

Giada Sebastiani, MD, FAASLD - Shedding Light on the Detection and Management of MASLD/MASH: Expert Insights to Improve Outcomes

Shannon Salvador, MD, MSc, FRCSC - Advancing Frontline Endometrial Cancer Care: Translating the Latest Advances in Immunotherapy Plus Chemotherapy Regimens to Practice

Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care

Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma

Versha Banerji, MD, FRCPC - The Ties That Bind: Exploring the Role of Noncovalent BTK Inhibitors in CLL Treatment

Rachel Goodwin, MD, MSc, FRCPC - Improving Care for Advanced Colorectal Cancer With Later-Line Treatments

Versha Banerji, MD, FRCPC - Raising the Bar: The Evolving Role of BTK Inhibitors in CLL Management

Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes

Christine Brezden-Masley, MD, PhD, FRCPC - Breaking Barriers: Expert Guidance on Best Strategies for Biomarker Testing in Gastric and GEJ Cancers

Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events

Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer

Alon Altman, MD, FRCSC - Upping the Ante in Advanced Endometrial Cancer Care: Optimizing the Use of Immunotherapy to Improve Patient Outcomes

Stephanie Snow, MD, FRCPC - Mastering HER2 in GI Malignancies: Immunotherapy and Chemotherapy Backbones for Optimal Patients Outcomes

Shaji Kumar, MD - Age Is More Than Just a Number: Tailoring Treatment Across the Multiple Myeloma Journey for Our Older and/or Unfit Patients

Mohamed El-Hussein, RN, PhD, NP / Caitlin Carreau, MN, RN(EC) - At the Forefront of Cancer Prevention: Nursing Strategies to Optimize HPV Immunization

Abdulazeez Salawu, MBBS, MSc, PhD - The Case for Biomarker-Guided Management of mCRC: Steps to Refine Care Along the Patient’s Journey

Matthew Kang, MD, FRCPC - Putting the Individual in ITP: Enhancing Patients Outcomes With TPO-RAs

Paul Wheatley-Price, MBChB, MD - The Track to Better Outcomes: Identifying and Managing Patients With NTRK-Positive Solid Tumours

Shawn Malone, MD, FRCPC - Maximizing Survival in mCRPC: Case-Based Guidance to Optimize Sequencing Decisions

Michael Chu, MD - A Smooth Ride: How to Optimize the Patient Journey With CAR T-Cell Therapy in Multiple Myeloma

Donna E. Reece, MD - Cases in Relapsed Refractory Multiple Myeloma: The Role of Anti-CD38–Based Regimens in an Evolving Canadian Landscape

Normand Blais, MD - Adjuvant Immunotherapy in Patients With Solid Tumours: Addressing Challenges With System Capacity in the Canadian Healthcare Setting

Eric Legius, MD, PhD - Building Blocks for Better Management of NF-1–Associated Plexiform Neurofibromas: Integrating New Evidence Into Canadian Clinical Practice

Brandon Sheffield, MD, FRCPC - Identifying Actionable Targets in Solid Tumours: The Importance of Comprehensive Genomic Profiling

Elena Castro, MD, PhD - Radioligand Therapy and Therapeutic Sequencing in mCRPC

Steven Mark Taylor, MD, FRCS(C), FACS - Beyond Face Value: The Case for Considering Immunotherapy in Locally Advanced cSCC

Christine Simmons, MD, MSc, FRCPC - Managing HR+/HER2- Metastatic Breast Cancer in the Community: Optimizing Safety to Maximize Benefit

Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not

Ken Herrmann, MD, MBA - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Aly-Khan A. Lalani, BSc(Hons), MD, FRCPC - Tailoring Immunotherapy-Based Combination Treatment in Advanced RCC: Key Updates to Refine Care

Aditya Bardia, MD, MPH - When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates for Hormone Receptor-Positive and Triple-Negative Breast Cancers

Richard LeBlanc, MD - BCMA-Targeted Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Why, Who, and When

Mita Manna, MD, FRCPC - CDK4/6 Inhibitors in HR+/HER2- High-Risk Early Breast Cancer: Considerations in Care

Kim N. Chi, MD, FRCPC / Steven Yip, MD, MSc, FRCPC - Personalizing Treatment Selection, Sequencing, and Future Opportunities for Patients With Advanced Prostate Cancer

Anna Tinker, MD, FRCPC - Maximizing Survival in Advanced or Recurrent Endometrial Cancer: The Evolving Role of Immunotherapy

Amit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC

Julie Stakiw, MD, FRCPC - Frailty Assessment and Improved Care in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients

Stephen Chia, MD, FRCP(C) - Keeping Abreast of the Latest Advances in HER2-Positive Metastatic Breast Cancer Treatment: Clinical Implications for the Canadian Landscape

Stephen Chia, MD, FRCPC - Exploring the Role of Immunotherapy in Triple-Negative Breast Cancer: A Turning Point for a Difficult-to-Treat Disease?

Sara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans

Hira Mian, MD, MSc, FRCPC - Moving the Needle in Relapsed Multiple Myeloma: Expert Insights to Address Key Questions in Patient Care

Laurie H. Sehn, MD, MPH - Clinical Update in the Treatment of Mantle Cell Lymphoma: The Evolving Evidence of BTK Inhibitors

John Storring, MD, CM, FRCPC - Current Therapeutic Strategies for Targeted Therapy Selection in De Novo Acute Myeloid Leukemia

Emmanuella Guenova, MD, PhD - ‘T’ing Up Management of Mycosis Fungoides and Sézary Syndrome: Evaluating Blood Involvement and Its Impact on Patient Care

Jun-ichi Nishimura, MD, PhD / Austin Kulasekararaj, MD, FRCPath / Jeffrey Szer, MBBS, FRACP - Haemolysis in Paroxysmal Nocturnal Haemoglobinuria: Applying Assessment and Mitigation Strategies for Patients Receiving Complement Inhibitors

Alicia K. Morgans, MD, MPH - What Would You Do Next? Exploring Expert Perspectives on Clinical Cases and Compelling Questions in mHSPC and nmCRPC

Alon Altman, MD, FRCSC - Aiming for Above Par Outcomes in Advanced Ovarian Cancer: The Role of Frontline Maintenance Therapy With PARP Inhibitors

Stephanie Snow, MD, FRCPC - The Next Frontier in Precision Medicine: Understanding the Role of Liquid Biopsy in Cancer Care

Christopher Venner, MD - Insights to Guide Early Recognition and Linkage to Care in AL Amyloidosis: An Expert Discussion

The Case for Better Care in Newly Diagnosed Multiple Myeloma: How Can We Improve Outcomes in Challenging Clinical Scenarios?

Adjuvant Therapy for Patients With Resected Melanoma: Finessing Care to Improve Survival in High-Risk Patients

The Next Frontier in Immunotherapy for Multiple Myeloma: What Will BCMA Targeting Mean for Our Relapsed/Refractory Patients?

Making Informed Treatment Choices for the Elderly Patient With CLL: A Look at the Evidence

Personalising Management of Advanced RCC: How I Treat

Immunotherapeutic Approaches in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Insights From the Real World

Immunotherapy in Advanced Endometrial Cancer: Challenges and Opportunities

Transforming Care With Adjuvant Immunotherapy in Muscle-Invasive Urothelial Carcinoma

More Than Skin Deep: Systemic Therapy for Advanced Cutaneous Squamous Cell Carcinoma

Upping the Ante: Considering Monoclonal Antibodies in Transplant Ineligible Newly Diagnosed Multiple Myeloma